Device Trial Radar · NCT04661111
Efficacy and Safety of Hymovis ONE® (32mg/4ml) Intrarticular Injection in Active Patients With Knee Overuse Syndrome
Last checked: Nov 19, 2026Latest source record: Dec 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Jun 13, 2016
Primary completion
Sep 28, 2017
Study completion Jun 28, 2018
Sponsor
- Lead sponsor
- Fidia Farmaceutici s.p.a.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy and safety of Hymovis® ONE (32 mg/4 ml) single intra-articular injection, in the management of pain caused by knee osteochondral lesions.
Conditions
- Knee Osteoarthritis
Interventions
Hymovis® ONE (32 mg/4 ml)Device
Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The efficacy of Hymovis® ONE (32 mg/4 ml) single intra-articular injection, in the management of pain caused by knee osteoarthritis due to overuse: KOOS questionnaire (Knee injury and Osteoarthritis Outcome Score)Time frame: Day 90 after baseline visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Università di Roma "La Sapienza", Azienda Policlinico Umberto I, Roma
Roma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.